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The tritiated arylazido phenylalkylamine (-)-5-[(3-azidophenethyl)[N-methyl-3H]methylamino]-2-(3,4,5-tri- 
methoxyphenyl)-2-isopropylvaleronitrile was synthesized and used to photoaffinity label the phenylalkyl- 
amine receptor of the membrane-bound and purified calcium channel from guinea-pig skeletal muscle trans- 
verse-tubule m~branes. The photoaffinity ligand binds reversibly to partially purified membranes with a 
K* of 2.0 Ir 0.5 nM and a B,, of 17.0 + 0.9 pmollmg protein. Binding is stereos~ifically regulated by 
all three classes of organic calcium channel drugs. A 155 kDa band was specifically photolabelled in trans- 
verse-tubule particulate and purified calcium channel preparations after ultraviolet irradiation. Additional 
minor labelled polypeptides (92,60 and 33 kDa) were only observed in membranes. The heterogeneous 155 
kDa region of the purified channel was resolved into two distinct silver-stained polypeptides after reduction 
(i.e. 155 and 135 kDa). Only the 155 kDa polypeptide carries the photoaffinity label and it is concluded 
that the 135 kDa polypeptide (which migrates as a 165 kDa band under alkylating conditions) is not a high- 
affinity drug receptor carrying subunit of the skeletal muscle transver~-tubule L-type calcium channel. 
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1. INTRODUCTION 
The skeletal muscle transverse-tubule membrane 
is the richest mammalian source of calcium chan- 
nel drug receptors [l]. Purification of the calcium 
channel from rabbit and guinea-pig skeletal muscle 
has been achieved employing radiolabelled 
I ,6dihydropyridines such as [3H]nitrendipine [2] 
and ( +)-[3H]PN 200-110 [3-61. The functional 
reconstitution of the purified preparations has also 
been reported [5,7]. Three major polypeptides with 
molecular masses of 135-170, 50-65 and 
30-35 kDa are usually co-purified together with 
1,4-dihydropyridine 12-61 or phenylalkylamine [S] 
binding activity. Photoaffinity labelling ex- 
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periments with the 1,4_dihydropyridine photoaf- 
finity probe [3H]a.zidopine identified the 155 kDa 
polypeptide region of the purified calcium channel 
from guinea-pig skeletal muscle as the 
1,4-dihydrop~dine receptor carrying component 
[6]. In order to answer the question as to which of 
the polypeptides carries the phenylalkylamine 
receptor, a potent, optically pure arylazido- 
phenylalkylamine was synthesized. Here we report 
the reversible binding characteristics of the novel 
ligand and the specific photolabelling of the 
phenyl~kyl~ine receptor of the membrane- 
bound and purified guinea-pig skeletal muscle 
calcium channel, 
2. MATERIALS AND METHODS 
2.1. waterways 
( -)-S-[(3-~idophenethyl)-[~-~et~y~-3H]meth- 
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ylaminol-2-(3,4,5-trimethoxyphenyl)-2-isopropyl- 
valeronitrile ([N-methy~-3H]LU49888) was syn- 
thesized by condensation of 3-azidophenethyl- 
amine with (-)-S-chloro-2-(3,4,5trimethoxy- 
phenyl)-2-isopropylvaleronitrile and subsequent 
N-methylation using [3H]methyl iodide. After 
purification by HPLC, the optically pure [N- 
methyC3H]LU49888 with a specific activity of 
85 Ci/mmol and a radiochemical purity > 98% 
was obtained. LU49888 was selected out of a 
group of azido derivatives of verapamil on the 
basis of its potent calcium antagonistic activity as 
determined by inhibition of K+-induced contrac- 
tion of rat aortic strips and of ( -)-[3H]desmethox- 
yverapamil binding (Raschack, M. and Unger, L., 
personal communication). The structure of the 
ligand is shown in fig.1. 
The sources for the unlabelled calcium channel 
drugs are given in [6,9]. Econofluor@ and 
Protosola were from New England Nuclear, 
Dreieich. 
2.2. Membrane and calcium channel preparation 
Guinea-pig partially purified transverse-tubule 
membranes were prepared as described [lo]. 
Calcium channels were purified from the mem- 
branes employing a rapid two-step purification 
procedure [6]. 
2.3. Binding assays and data calculation 
Reversible binding of [N-methyl-3H]LU49888 to 
membrane-bound and purified calcium channels 
was measured in 50 mM Tris-HCl buffer (pH 7.4) 
at 25°C as described for (-)-[‘Hldesmethox- 
yverapamil [6,9] in the absence of ultraviolet light. 
Nonspecific binding was determined in the 
presence of 1 pM (membranes) or 3 PM ( -)- 
desmethoxyverapamil (purified calcium channel) 
and was subtracted from total binding to yield 
specific binding. The association rate constant was 
calculated using the pseudo-first-order ate equa- 
tion. Dissociation of the [N-methyl-3H]LU49888- 
receptor complex at equilibrium was initiated by 
80-fold dilution of the incubation mixture with 
buffer. The dissociation rate constant was 
calculated by linear methods as in [I 11. Means f 
SD from at least three independent experiments are 
given. Binding-inhibition data were fitted with 
non-linear methods [ 111. 
2.4. Photoaffinity labelling experiments 
Photoaffinity labelling experiments with 
membrane-bound calcium channels were carried 
out as described for [3H]azidopine [12,131 employ- 
ing 2.3-14.5 nM [N-methyl-3H]LU49888 and 
0.4-0.7 mg membrane protein. Photoaffinity 
labelling experiments with purified calcium chan- 
nels were carried out in a total volume of 1.5 ml 
employing 15- 18 nM [N-methyl-3H]LU49888 and 
4-6 pg purified protein as described for (-)- 
[3H]azidopine [a]. Nonspecific incorporation was 
defined as labelling in the presence of 1 pM (mem- 
branes) or 3 PM ( - )-desmethoxyverapamil 
(purified calcium channel). SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) was carried out as 
described with either 10 mM N-ethylmaleimide 
(alkylating conditions) or 10 mM dithiothreitol 
(reducing conditions) in the sample buffer [ 131. To 
quantitate the amount of incorporated [N- 
methyC3H]LU49888, gels were cut into 2 or 3 mm 
slices and radioactivity determined after extraction 
with Econofluor@ containing 3% Protosol@. 
3. RESULTS 
3.1. Reversible /N-methyl-3HJL U49888 binding to 
partially purified skeletal muscle transverse- 
tubule membranes 
Reversible specific binding of [N-methyl- 
‘HlLU49888 was linear with respect o membrane 
protein up to a concentration of 0.060 mg/ml. No 
saturable binding of the ligand to glass fiber filters 
was observed under our assay conditions. Binding 
was pH-dependent with a binding optimum be- 
tween pH 7.0 and 8.0 (not shown). The association 
reaction of [N-methyl-3H]LU49888 was rapid at 
25°C reaching a steady state within 20 min when 
2-3 nM ligand and 0.35-0.70 nM drug receptor 
were employed. Using the first-order rate equation 
a k+l of 0.072 f 0.006 nM_’ -miner (n = 3) was 
calculated. Dissociation kinetics of the [N-methyl- 
3H 1 LU49888-receptor complex after dilution were 
mono-exponential with a tl/z of 3.9 min at 25°C 
(k-1 = 0.179 + 0.021 min-‘; n = 3). The saturation 
isotherm of [N-methyl-3H]LU49888 was mono- 
phasic with a Kd of 2.0 + 0.5 nM and a B,,,,, of 
17.0 f 0.9 pmol/mg protein (means + SD from 4 
experiments) at 25°C. A representative xperiment 
is shown in fig.1. The Kd (2.5 nM), calculated 
from the kinetic constants, was in fair agreement 
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Fig. 1. Saturation isotherm of [N-methyl-3H]LU49888 binding to guinea-pig partially purified skeletal muscle 
membranes. (A) Increasing concentrations (0.1-18 nM) of [N-methyl-3H]LU49888 were incubated with 6.3 pg 
membrane protein at 25°C in a total assay volume of 0.25 ml for 45 min. Binding in the presence of 1 pM (-)- 
desmethoxyverapamil (A , nonspecific binding) was subtracted from total binding to yield specific binding (0). (B) 
Hofstee transformation of the equilibrium binding data. The correlation coefficient was 0.99, the B,,,, = 404.3 nM 
(= 16 pmol/mg protein) and the Ka = 1.6 nM. Means from triplicate determinations. (Inset) Structural formula of [N- 
methyl-‘HlLU49888. 
with the Kd determined by equilibrium saturation 
analysis. [N-methyl-3H]LU49888 binding is stereo- 
selectively regulated by all three classes of organic 
calcium channel blockers (fig.aA-C) in a manner 
very similar to ( -)-[3H]desmethoxyverapamil 
binding [9]. Reversible binding is also inhibited by 
Cd2+ and Ca2+ (fig.2D) and by La3+ (IC50 = 32.0 
Fig.2. Binding-inhibition studies. 0.8-l .6 nM [N- 
methyC3H]LU49888 were incubated with 4.2-6.8 pg 
membrane protein in the absence or presence of drugs or 
divalent cations (triplicate or duplicate assays). Specific 
binding in the presence of added drug was normalized 
with respect o control binding (100%). Pooled binding- 
inhibition data from 3 independent experiments are 
shown. Points are means f SD. Binding parameters are 
given f asymptotic SD. Ki values for competitive 
inhibitors were calculated according to Linden [23]. ICSO 
values are given for noncompetitive inhibitors. (A) 
1,4_Dihydropyridines: (+)-PN 200-110: ICSO = 1.43 f 
0.18 nM, nu = 1.70 f 0.33, maximal inhibition to 46 f 
4% of control binding at this ligand concentration; ( - )- 
PN 200-110: I& = 489 f 105 nM, nu = 0.63 f 0.07. 
(B) Phenylalkylamines: ( - )-desmethoxyverapamil 
(D-888): Ki = 5.7 +- 1.0 nM, trn = 0.98 f 0.15; (+)- 
desmethoxyverapamil: Ki = 24.4 f 3.2 nM, nu = 1.05 f 
6 5 4 
DRUG[-loOW).M] 
0.12; (*)-tiapamil: Ki = 146 f 17 nM, nu = 1.41 f 0.21; 
(*)-D619: Ki = 5.6 f 0.61 PM, nu = 0.98 + 0.09. (C) 
Benzothiazepines: d-cis-diltiazem: I&O = 163.6 + 
27.5 nM, ?rH = 0.79 f 0.10; I-cis-diltiazem: I& = 
9.14 f 0.12 pM, nH = 1.04 f 0.12. (D) Divalent cations: 
Cd’+: I& = 15.9 f l.lOaM, nu = 1.89 f 0.19; Ca*+: 
ICSO = 820 f 270pM; nH = 0.66 f 0.09, maximal 
inhibition to 10 f 8% of control binding. 
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+ 9 PM). Depletion of divalent cations from mem- 
branes by incubation with increasing concentra- 
tions of EDTA at 25°C caused only partial 
inhibition (30%) of binding at EDTA > 10 mM 
(not shown). 
3.2. Properties of reversible [N-methyl-jH]- 
LU49888 binding to purified calcium 
channels 
The dissociation constant for ( -)-[3H]- 
desmethoxyverapamil increases 15-35fold 
upon calcium channel purification [8]. A similar 
loss of affinity was observed when [N- 
methyl-3H]LU49888 binding to purified channel 
preparations was investigated. The Kd (at 2YC) 
was 62 + 11 nM (n = 3). (-)-Desmethoxyverapamil 
was a competitive inhibitor (Ki = 40 + 12 nM) and 
twice as potent as (+ )-desmethoxyverapamil (Ki = 
94 + 20 nM). The pharmacologically less potent 
phenylalkylamine (+)-D619 [9] was only a weak 
competitor of reversible [N-methyl-3H]LU49888 
binding in purified preparations (IGO = 44 + 
11 PM). The interaction of the ligand with the 
purified receptor is stereoselectively regulated by 
the enantiomers of the benzodadiazole 
1 ,Cdihydropyridine PN 200- 110. (+ )-PN 200-l 10 
allosterically stimulates reversible binding (EC50 = 
21 f 5 nM, maximal stimulation to 238 + 61% of 
control binding) whereas the respective (-)- 
enantiomer was without effect up to 1 pM (not 
shown). 
3.3. Photolabelling of the phenylalkylamine 
receptor 
Fig.3A,B shows the quantitative analysis of a 
representative [N-methyl-3H]LU49888 photola- 
belling experiment with transverse-tubule mem- 
branes. Four polypeptides with apparent 
molecular masses of 155 + 3, 92 f 2, 60 + 3 and 
33 it 3 kDa (means + SD from 5 experiments), 
termed a-d, are photolabelled. The incorporation 
of [N-methyl-3H]LU49888 into these bands was in- 
hibited by 1 pM ( - )-desmethoxyverapamil but not 
by 1 PM ( + )-D619. 3 ,uM d-cis-diltiazem caused 
only partial inhibition. Thus, the protection profile 
shows the same pharmacological regulation by dif- 
Fig.3. Photoaffinity labelling of the membrane-bound 
(A,B) and purified calcium channel (C) with [N- 
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methyl-‘HlLU49888. Photoaffinity labelling experi- 
ments and SDS-PAGE were carried out as described 
[ 131. 2.42 nM [N-methyl-3H]LU49888 was incubated 
with 0.62 mg membrane protein for 45 min at 25°C. (A) 
4.3 pmol [N-meth_vl-3H]LU49888 were reversibly bound 
in the absence (0, total binding lane) and 0.27 pmol in 
the presence (0, nonspecific binding lane) of (-)- 
desmethoxyverapamil prior to irradiation. (B) 3.9 pmol 
[N-methyl-3H]LU49888 were reversibly bound in the 
absence (0) of added drug, 3.8 pmol in the presence of 
1 ,uM (+)-D619 (0) and 2.1 pmol in the presence of 
3 pM d-cis-diltiazem (A) prior to irradiation. (C) 
17.8 nM [N-methyl-3H]LU49888 was incubated with 
4.7 pg purified calcium channel protein for 45 min at 
25°C and irradiated as described in [6]. 2.6 pmol [N- 
methyC’HlLU49888 were specifically bound in the 
absence of added drug (0, total binding lane), 
0.57 pm01 in the presence of 3fiM (-)- 
desmethoxyverapamil (0, nonspecific binding lane) and 
2.1 pmol in the presence of 3 pM ( + )-D619 (A) prior to 
irradiation. 
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ferent calcium channel drugs as reversible binding. 
Specifically incorporated radioactivity was 
distributed as follows: a = 62 + 10, b = 12 f 1070, 
c = 14 f 10, d = 12 f 3% (means + SD from 3 
experiments). No difference in the apparent 
molecular mass of the labelled bands was observed 
when the samples were separated on SDS-PAGE 
under reducing conditions (not shown). The effi- 
ciency of specific photoincorporation (as a percen- 
tage of reversibly bound ligand was 0.2 f 0.04070, 
somewhat lower than that of the 1,4-di- 
hydropyridine photoaffinity label [3H]azido- 
pine [13]. 
In the purified calcium channel preparation 
three polypeptides with apparent molecular masses 
of 155, 65 and 32 kDa were identified after SDS- 
PAGE under alkylating conditions [6]. Only the 
155 kDa polypeptide region was specifically la- 
belled by [N-methyl-3H]LU49888. Photolabelling 
was completely inhibited by 3 /IM ( -)-desmeth- 
oxyverapamil but not by 3 pM (+)-D619 (fig.3). 
The 155 kDa polypeptide region is a broad diffuse 
silver-stained band under alkylating conditions of 
electrophoresis in 5-15070 gradient gels [2,5,6]. 
However, we observed that in 8% polyacrylamide 
gels the heterogeneity of this region is more ap- 
parent (see fig.4) and two polypeptides with ap- 
parent molecular masses of 155 + 2 and 165 -t 
3 kDa (n = 5) can be partly resolved under 
alkylating conditions. Under reducing conditions 
of SDS-PAGE two distinct migrating polypeptides 
of 155 + 3 and 135 + 2 kDa (n = 5) can be clearly 
identified by silver staining (fig.4). To determine 
exactly which of these polypeptides carried the ir- 
reversibly incorporated ligand, purified channels 
were separated after photolabelling under reducing 
and alkylating conditions by SDS-PAGE. Gels 
were stained and radioactivity in the stained bands 
was quantitated. It was found that a 155 + 3 kDa 
(n = 3) polypeptide which does not alter its mobili- 
ty upon reduction contained more than 90% of the 
incorporated label. A representative xperiment is 
shown in fig.4. The extent of photoincorporation 
was 0.8 f 0.1% (n = 3) in the purified preparation. 
1c 
C 
Fig.4. 
155 kDa 
I 
165 kDa 
I 
155 kDa 
I 
%LlCE NUMBER 
155 kDa 
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Identification of the [N-methyl-‘H]LU49888- 
155 kDa 
I 
labelled polypeptide in purified calcium channel 
preparations. Purified calcium channels (5.1 yg protein) 
were photolabelled, employing 15.1 nM [N-methyl-3H]- 
LU49888. The irradiated samples were separated on an 
8% polyacrylamide gel under alkylating (10 mM N- 
ethylmaleimide, NEM; left panel) and reducing (10 mM 
dithiothreitol, DTT; right panel) conditions. The gel was 
stained with silver and scanned on an LKB Ultroscan 
laser densitometer. Gel lanes were subsequently cut into 
2 mm slices and the radioactivity determined by liquid 
scintillation counting. The figure shows the results from 
the top of the gel (slice no. 1) to the 100 kDa region (slice 
no.20). Incorporated radioactivity in the absence (open 
columns) and presence (hatched columns) of 3 PM (-)- 
desmethoxyverapamil (upper panel) is shown in 
comparison with the densitometric s an (lower panel). 
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4. DISCUSSION 
The arylazidophenylalkylamine, [N-methyl- 
‘HlLU49888, exhibits similar binding character- 
istics to (-)-[‘Hldesmethoxyverapamil. The latter 
is a high-affinity, high-specific-activity ligand for 
calcium channel-linked phenylalkylamine recep- 
tors in skeletal muscle [9,14,15], brain [15,16] and 
heart [17,18]. Our data show that [N-meth~/-3H]- 
LU49888 labels phenylalkylamine receptors in 
skeletal muscle in the absence of ultraviolet light 
with a Kd value of 2.0 nM, almost identical with 
that of ( - )-[3H]desmethoxyverapamil [9]. After 
photolysis of [iV-methyl-3H]LU49888-labelled 
membranes, the ligand covalently incorporated in- 
to four bands (a-d) with apparent molecular 
masses of 155, 92, 60 and 33 kDa after separation 
by SDS-PAGE. The protection profile of incor- 
poration into these bands was identical to the 
regulation of reversible [N-methyl-3H]LU49888 
binding. This is convincing evidence for the phar- 
macological specificity. 62% of the specifically in- 
corporated radioactivity was recovered in the 
155 kDa region. The irreversibly labelled 155 kDa 
polypeptide had identical electrophoretic mobility 
under reducing and alkylating SDS-PAGE condi- 
tions when the particulate calcium channel pre- 
paration was investigated. In contrast to the 
membrane-bound channel, specific photolabelling 
in the 92, 60 and 33 kDa region of the purified 
channel was not observed. Perhaps, these lower 
molecular mass polypeptides are proteolytic 
fragments of the drug-receptor carrying channel 
component which are lost upon purification. 
Similar findings have been reported for [‘Hlazi- 
dopine which can also specifically photoincor- 
porate to a minor extent into lower molecular mass 
membrane polypeptides [ 131 but only labels the 
155 kDa polypeptide region in the purified channel 
preparation [6]. Employing reducing conditions in 
SDS-PAGE the 155 kDa region of the purified 
channel was clearly resolved into two distinct 
polypeptides. The 155 kDa polypeptide had iden- 
tical electrophoretic mobility under both (al- 
kylating and reducing) conditions and carries the 
specifically incorporated photoaffinity label 
observed in the purified preparation. The other 
polypeptide (165 kDa under alkylating conditions) 
changes its mobility, has an apparent molecular 
mass of 135 kDa after reduction and was not 
252 
photolabelled. This polypeptide has similar elec- 
trophoretic properties to the protein identified by 
immunoblotting, claimed to carry the 1,4-di- 
hydropyridine receptor [19,20]. As only L-type 
calcium channels in skeletal muscle preparations 
are sensitive to 1 ,Cdihydropyridines and phenyl- 
alkylamines [21,22], we conclude that the 155 kDa 
and not the 135 kDa polypeptide is the high- 
affinity phenylalkylamine receptor carrying 
subunit of the L-type calcium channel. We suggest 
that amino acid sequences from the 155 kDa [N- 
methyl-3H]LU49888-photolabelled polypeptide of 
the purified channel are the most promising ap- 
proach for the generation of oligonucleotides. 
These should be used for the screening of cDNA 
libraries in order to obtain the primary structure of 
the drug-receptor carrying calcium channel 
subunit. 
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